We’re excited to announce a major milestone: the Italian government has granted regulatory clearance under the Golden Power regulation for our planned acquisition of Pincell S.r.l., a pioneering Italian biotech company.
“We are pleased to have received this regulatory clearance, which represents a significant step forward in our planned acquisition of PinCell,”said Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.
PinCell srl’s lead candidate, PC111, is a fully human monoclonal antibody targeting the Fas/FasL pathway, in development for severe autoimmune skin diseases including Pemphigus, Stevens-Johnson Syndrome (SJS), and Toxic Epidermal Necrolysis (TEN). PC111 has already received Orphan Drug Designation from the EMA for Pemphigus.
In parallel, Scinai’s Polish subsidiary has submitted a €12M grant application under the FENG program to fund the next stage of PC111’s development, with a decision expected later this summer.
This regulatory green light marks a key advancement in our journey—reinforcing Scinai’s growing role in biotech innovation and our commitment to delivering impactful therapies to patients worldwide.
Read the full press release: Https://https://lnkd.in/dUKiEm73
